Results 91 to 100 of about 681,456 (227)

A cost‐effectiveness analysis of breast cancer treatment in certified versus non‐certified hospitals in Germany

International Journal of Cancer, Volume 159, Issue 1, Page 159-172, 1 July 2026.
What's New? This study is the first to quantify the cost‐effectiveness of breast cancer treatment in German Cancer Society‐certified hospitals using real‐world data from over 140,000 patients. Analysis on certification‐related costs and survival outcomes demonstrates that high‐quality multidisciplinary care at certified hospitals delivers substantial ...
Min‐Wai Lwin, Olaf Schoffer, Christoph Streissnig, Pauline Wimberger, Michael Gerken, Veronika Bierbaum, Christoph Bobeth, Martin Rößler, Patrik Dröge, Thomas Ruhnke, Christian Günster, Kees Kleihues‐van Tol, Theresa Link, Anton Scharl, Elisabeth C. Sturm‐Inwald, Karin Kast, Thomas Papathemelis, Olaf Ortmann, Monika Klinkhammer‐Schalke, Jochen Schmitt, Michael Schlander   +20 more
wiley   +1 more source

Development of a step‐gradient simulated moving bed process for the polishing of monoclonal antibodies with anion exchange chromatography

Journal of Chemical Technology &Biotechnology, Volume 101, Issue 7, Page 1359-1369, July 2026.
Abstract BACKGROUND In recent years, biopharmaceutical applications in medicine have seen explosive growth and the need for efficient, rapid and inexpensive purification of these targets is the topic of tremendous research and development. The need to improve process efficiency has been an active area of investigation due to the tremendous potential ...
Yasmina MJ Harsy, Jonas Wege, Anthony Grabski, Romain Dabre, Egbert Müller, Carsten‐René Arlt   +5 more
wiley   +1 more source

Real-Life Clinical Effectiveness of Razumab® (World’s First Biosimilar Ranibizumab) in Wet Age- Related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion: A Retrospective Pooled Analysis

International Journal of Ophthalmology & Eye Science, 2018
Purpose: To evaluate the effectiveness of Razumab^® (world's first biosimilar ranibizumab; Intas Pharmaceuticals Ltd., India) in Indian patients with wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and retinal vein occlusion (
S. Sharma, K. Ma, A. Chaturvedi
semanticscholar   +1 more source

The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long‐Acting Insulin Analogues for Diabetes Mellitus

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5527-5541, July 2026.
ABSTRACT In the year 2000 the first once daily long‐acting bioengineered insulin analogue (LAIA), insulin glargine (‘glargine’), a true basal insulin (BI), became available for clinical use. This led to the decline in the 50‐year‐old era and prominence of the intermediate‐acting insulins, neutral protamine Hagedorn (NPH) and lente, requiring twice ...
Geremia B. Bolli, Philip D. Home, Mauro Lepore, Matthew C. Riddle, Francesca Porcellati, Carmine G. Fanelli, Paola Lucidi, Hannele Yki‐Järvinen, Reinhard H. Becker, David R. Owens   +9 more
wiley   +1 more source

Retrospective Analysis of HER2 Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC With HER2 Mutations in France

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT Background HER2 (ERBB2) gene mutations are associated with poor prognosis in non‐small cell lung cancer (NSCLC). It is important to identify patients with HER2‐mutant (HER2m) NSCLC, as new targeted treatment options are emerging. However, HER2 testing in clinical practice varies across regions, and real‐world data on HER2m NSCLC are limited ...
Didier Debieuvre, Pauline Macouillard, Xavier Quantin, Mehmet Berktas, Nicolas Girard, Clarisse Audigier‐Valette, Thomas Filleron, Stefania Musilli, Lise Bosquet, Maurice Pérol   +9 more
wiley   +1 more source

Immunopharmacology 2020. V International Congress on Immunopharmacology

VacciMonitor, 2020
The Organizing Committee of the “V International Congress on Immunopharmacology” (Immunopharmacology 2020) organized by the Cuban Society of Pharmacology, BioCubaFarma and the International Union of Basic and Clinical Pharmacology (IUPHAR) would like to ...
Mario Landys Chovel Cuervo, Silvio Perea
doaj  

From small molecule generics to biosimilars: Technological upgrading and patterns of distinctive learning processes in the Indian pharmaceutical industry [PDF]

Technological Forecasting and Social Change, 2019
Technology upgrading is a key element of industrialisation and catch-up in developing countries. It is understood that a successful technology upgrading is linked to a coupling of global knowledge flows with local technology effort. However, the changing nature of technology and industries are challenging existing processes involved in the technology ...
openaire   +1 more source

Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do Matter

Clinical Pharmacology & Therapeutics
There are no clinically meaningful differences between bio‐originators (BO) and their biosimilars (BS) in safety and efficacy. However, differences in pharmaceutical properties, such as volume and excipient, can occur. This study aimed to compare outcomes between patients transitioning from the modernized adalimumab BO (0.4 mL/no ...
Amy C.D. Peeters, Maike H.M. Wientjes, Wieland D. Müskens, David F. Ten Cate, Laura C. Coates, Bart J. F. van den Bemt, Noortje van Herwaarden, Alfons A. den Broeder   +7 more
openaire   +3 more sources

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1522-1536, June 2026.
Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra, Viktoriia Starokozhko, Elisabeth Bakker, Anna Maria Gerdina Pasmooij, Peter Gerardus Maria Mol   +4 more
wiley   +1 more source

Moving beyond a legacy paradigm: A vision for equitable access to quality medicines in Africa

International Journal of Gynecology &Obstetrics, Volume 172, Issue S2, Page S44-S50, June 2026.
Abstract Ensuring the availability of quality medicines is fundamental to achieving health outcomes and safeguarding public health. However, in many low‐ and middle‐income countries, especially across Africa, the current quality assurance paradigm—largely driven by historical donor preferences for WHO prequalification and stringent regulatory authority
Naoko Doi, Bright C. Orji, Michael Ruffo, Philippe Mukumbayi, Samuel Kibonge, Michael Mwiti Muthamia, Hannah Tappis, Franck Biayi, Talatu Y. Kassim, Albert Ndwiga   +9 more
wiley   +1 more source